Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Trial Profile

Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms PREDICT
  • Most Recent Events

    • 04 Dec 2013 New trial record
    • 30 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-003533-16).
    • 21 Nov 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top